Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility
Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility
复制标题
DOI：
10.1093/cid/ciy762
复制
发表时间：
2019-05-15
影响因子：
11.8
通讯作者：
Kaul, Rupert
中科院分区：
文献类型：
--
作者：
Joag, Vineet;Obila, Onyango;Kaul, Rupert
背景资料。生殖器免疫学是人类免疫缺陷病毒(HIV)易感性的关键决定因素。这两个因素都受到细菌性阴道病(BV)的调节，在某种程度上，还受到生殖器乳杆菌属(Lactobacillusspp)的调节。这在非洲、加勒比海和其他黑人(ACB)女性中占主导地位。我们进行了一项临床试验，以评估口服甲硝唑治疗对感染艾滋病毒的肯尼亚妇女的生殖器免疫参数的影响。主要终点是1个月后宫颈CD4+T细胞HIV的体外易感性；次要终点包括生殖器细胞因子/趋化因子水平、宫颈免疫细胞群以及16S核糖体RNA基因扩增序列测定宫颈阴道微生物群的组成。BV已解决(纽金特分数
Background. Genital immunology is a key determinant of human immunodeficiency virus (HIV) susceptibility. Both factors are modulated by bacterial vaginosis (BV) and, to some extent, by Lactobacillus iners, the genital Lactobacillus spp. that predominates in African, Caribbean, and other Black (ACB) women. We conducted a clinical trial to assess the impact of oral metronidazole treatment on the genital immune parameters of HIV acquisition risks in Kenyan women with BV.Methods. The primary endpoint was ex vivo cervical CD4+ T-cell HIV susceptibility after 1 month; secondary endpoints included genital cytokine/chemokine levels, cervical immune cell populations, and the composition of the cervico-vaginal microbiota by 16S ribosomal RNA gene amplicon sequencing.Results. BV resolved (Nugent score